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Abstract
Previous studies in vivo have shown that IL-10 infusion
can prevent lethal endotoxic shock. Mice deficient in the
production of IL-10 (IL1OT) were used to investigate the
regulatory role of IL-10 in the responses to LPS in three
experimental systems. In a model of acute endotoxic shock,
it was found that the lethal dose of LPS for IL1OT mice was
20-fold lower than that for wild type (wt) mice suggesting
that endogenous IL-10 determines the amount of LPS which
can be tolerated without death. The high mortality rate of
IL1OT mice challenged with modest doses of LPS was corre-
lated to the uncontrolled production of TNF as treatment
with anti-TNF antibody (Ab) resulted in 70% survival. Ad-
ditional studies suggested that IL-10 mediates protection by
controlling the early effectors of endotoxic shock (e.g.,
TNFa) and that it is incapable of directly antagonizing the
production and/or actions of late appearing effector mole-
cules (e.g., nitric oxide). We also found that ILAOT mice
were extremely vulnerable to a generalized Shwartzman re-
action where prior exposure to a small amount of LPS
primes the host for a lethal response to a subsequent suble-
thal dose. The priming LPS dose for IL1OT mice was 100-
fold lower than that required to prime wt mice implying
that IL-10 is important for suppressing sensitization. In
agreement with this assumption, IL-10 infusion was found
to block the sensitization step. Interestingly, IL-10 was not
the main effector of endotoxin tolerance as ILAOT mice could
be tolerized to LPS. Furthermore, IL-10 infusion could not
substitute for the desensitizing dose of LPS. These results
show that IL-10 is a critical component of the host's natural
defense against the development of pathologic responses to
LPS although it is not responsible for LPS-induced toler-
ance. (J. Clin. Invest. 1995. 96:2339-2347.) Key words: IL-
10 * endotoxic shock * Shwartzman reaction * endotoxin
tolerance
Introduction
Severe gram-negative bacterial infections can lead to the devel-
opment of endotoxic shock, a state characterized by hypoten-
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sion, multiorgan failure, and potentially death. This syndrome
is secondary to the effects of endotoxin, the LPS-containing
portion of the bacterial cell wall. Infusion of LPS mimics the
endotoxic shock state (1) and results in the production of multi-
ple inflammatory cytokines, including TNFa (2, 3), IL-1 (4,
5), and IFNy (6). The toxicity of LPS appears to be mediated
by these cytokines as passive immunization against these media-
tors resulted in decreased mortality (2, 6-10).
There has been considerable interest in the fact that LPS
induces not only the production of pro-inflammatory but also
the production of anti-inflammatory molecules such as IL-10
( 11). IL-1O has been shown to be a potent macrophage deacti-
vator, blocking the induced synthesis of TNFa, IL- 1, IL-6, IL-8,
and GM-CSF by human monocytes (12) and mouse peritoneal
macrophages (13). IL-10 also indirectly suppresses the synthe-
sis of IFNy by helper T cells (14) and NK cells (15). Based
on the results of these in vitro studies, it was proposed that IL-
10 may be useful in the treatment of endotoxic shock. Subse-
quently, it was shown that a single injection of IL-10 prevented
death in murine models of LPS-induced toxic shock (16, 17).
Maximum protection was afforded only when IL-10 was given
shortly before or within 30 min after LPS challenge. Although
these studies left little doubt that IL-10 could function as a
potent anti-inflammatory agent, it seemed unlikely that it could
be used to treat patients already presenting with symptoms of
toxic shock. It was also questionable whether endogenously
produced IL-10 was normally involved in suppressing endo-
toxin-induced toxicity since in vitro studies had shown that the
synthesis of IL-10 by LPS-stimulated macrophages occurred
late (18-24 h) relative to that of pro-inflammatory cytokines
(2-6 h) (12). Recently it was found that IL-10 is produced in
mice very rapidly after exposure to LPS ( 18, 19). In fact, serum
IL-10 levels peaked at the same time as TNFa, which is known
to play a central role in the pathogenesis of endotoxic shock
(3). Furthermore, administering neutralizing anti-IL-10 Ab to
mice before challenge with a sublethal dose of LPS resulted in
greatly increased serum IFNy and TNF levels and in a 60%
mortality rate (19). These studies first suggested a regulatory
role for endogenous IL-10 in endotoxic shock.
The generation of mice with a targeted disruption of the IL-
10 gene (ILlOT)1(20) has allowed further definition of the
actions of IL-10 in complex physiologic systems. We have com-
pared the LPS responses of ILlOT and wt mice to determine
the importance of endogenous IL-10 in regulating immune/
pathologic responses in an endotoxic shock model (17), the
generalized Shwartzman reaction (a model of disseminated in-
1. Abbreviations used in this paper: Ab, antibody; f.p., footpad; i.p.,
intraperitoneal; i.v., intravenous; ILIOT, mice with a targeted disruption
of the IL-10 gene; wt, wild type.
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travascular coagulation and shock) (21, 22), and acquired endo-
toxin tolerance (23, 24).
Methods
Animals. ILIOT mice generated on a C57B1/6/129-Ola background
(20) and wt litter-mate controls were derived by cesarean section at
Simonsen Laboratory (Gilroy, CA) and maintained in our animal facility
at DNAX (Palo Alto, CA). Healthy 4-5 wk old ILIOT mice were used
for this study.
Reagents. LPS from Escherichia coli (serotype 0111 :B4) was ob-
tained from DIFCO (Detroit, MI) and resuspended in pyrogen-free
saline. Recombinant murine IL-10 was expressed in E. coli as inclusion
bodies and purified after renaturation to homogeneity and high sp act
(_ 1.0 X 107 U/mg) using hydrophobic and ion exchange chromatogra-
phy. The protein concentration in the purified preparations was deter-
mined by the extinction coefficient of the protein (1 mg/ml = 0.36
A280). This material contained < 0.10 EU/mg protein, and remained
stable at 40C for at least 6 mo. The specific activity of murine IL-10
was evaluated in a proliferation assay using Ba/F3 cells carrying the
IL-10 receptor (25). Recombinant IL-10 was diluted in saline and a
dose of 10 Mg/mouse, i.p., was administered in a total volume of
250 Ml.
Determination of serum cytokine and NO levels. Blood samples
were obtained by cardiac puncture from mice euthanized with CO2.
Serum concentrations of TNFa and IL- a were measured using ELISA
kits purchased from Genzyme (Boston, MA) as per the manufacturer's
directions. Other serum cytokine levels were detected by two-site sand-
wich ELISA assays as previously described (26), using the following
antibody pairs which were kindly provided by Dr. J. Abrams (DNAX):
for IFNy, R46A2, and AN18; for IL-6, 32C1 1, and 20F3; and for IL-
10, SXC-1 1, and XT3. The antibodies to the p40 subunit of IL-12,
C15.1.2 and C15.6.7 (27) were kindly provided by Anne O'Garra
(DNAX). Biological activity of the IL-12 heterodimer was quantified
by an Ab capture bioassay as previously described (28). Murine rIL-
12 purified from the supernatant of COS 7 cells transfected with the
cDNAs encoding the p35 and p40 subunits of IL- 12 was kindly provided
by Dr. M. Bond, DNAX. Serum nitrate levels were measured by reduc-
ing nitrate enzymatically with nitrate reductase (29). Serum was diluted
1:5 in water and the enzyme reaction was performed using a kit pur-
chased from Boehringer-Mannheim (Indianapolis, IN) as per the manu-
facturer's direction.
Experimental protocol for induction of endotoxic shock. Mice were
injected i.v. via the tail vein with LPS (2.5, 5, 10, 50, 100, or 200 mg/
mouse) in a saline solution of 200M1 per dose and monitored for survival
for 7 d. All deaths occurred within 3 d of LPS administration. All
protocols were reviewed and approved by the institute's (DNAX) ani-
mal care committee.
Treatment with anti-cytokine antibodies. Wt and IL1OT Mice were
injected intraperitoneally with various concentrations of purified rat
anti-mouse neutralizing anti-cytokine Abs or isotype control Abs (2,
5, or 10 mg). These Abs were administered either 4 h before, concurrent
with or 2, 4, or 6 h after LPS administration as indicated in the result's
section. Antibodies used herein were: anti-IL-10 (JESS-2A5); anti-IL-
6 (20F3); anti-TNF (XT22); anti-IFNy (XMGI .2); and anti- ,6-galac-
tosidase (GL-117) which is referred to as the isotype control. The anti-
TNF antibody, XT22, was elicited against TNFa but neutralizes both
TNFa and TNF,/. The antibody concentrations used herein have been
shown to block the adverse affects of LPS in wt mice (when possible).
The highest concentrations used (10 mg/mouse) were 2- to 5-fold higher
than those required to ablate the adverse affects of endogenously pro-
duced cytokines in normal mice in a model of LPS-induced toxic shock
(19) or in other in vivo models (30, 31, 32).
Experimental protocolfor the generalized Shwartzman reaction and
endotoxin tolerance. The generalized Shwartzman reaction and endo-
toxin tolerance were elicited in mice by two consecutive injections of
E. coli LPS. A preparatory injection was given in varying doses in the
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Figure 1. ILIOT mice have increased susceptibility to endotoxic shock.
ILIOT and wt mice were injected with the indicated doses of LPS i.v.
and monitored for survival for 7 d. Each treatment group consisted of
6-8 wt or ILIOT mice. Results are expressed as percentage of survival
and are representative of three independent experiments.
f.p. followed 24 h later by an i.v. provoking dose (elicitation). The
preparatory dose for the Shwartzman reaction in ILIOT mice was 0.005
to 0.01 pig LPS; in wt mice the dose was 1 Mlg. The provoking dose for
the ILIOT mice was 2.5 Mg; for wt mice the dose was 100 Mug. The
preparatory dose for endotoxin tolerance in ILIOT mice was 1.0 Mg; in
wt mice the dose was 25 Mg. The provoking dose for the ILIOT mice
was 5-10 Mg; for wt mice the dose was 200 Mg. In some experiments,
serum was obtained at varying intervals after LPS injection (provoking
dose) for measurement of cytokine levels, in the manner described
above.
Statistical analysis. Significant differences between experimental
groups were evaluated by the nonparametric Mann and Whitney U test.
Results
ILMOT mice show increased mortality rates and dysregulated
cytokine production in a model of endotoxic shock. We com-
pared the responses of ILIOT and wt mice after challenge with
varying doses of LPS. ILIOT mice were extremely sensitive to
LPS as none survived a dose as low as 5 dig/mouse (Fig. 1).
In contrast, wt mice survived a dose of 100 jag/mouse. These
results suggested that endogenous IL-10 is important for estab-
lishing the lethal threshold dose of LPS in wt mice at a 20-fold
higher level than that observed in ILIOT mice.
Cytokine levels in the sera of ILlOT and wt mice were
measured at various intervals after LPS administration. The
dose of LPS used for this experiment was 50 jag/mouse as it
produced 100% mortality in ILlOT mice and no mortality in
wt mice (refer to Fig. 1). It was found that TNFa levels were
greatly increased in ILlOT mice as compared with wt mice
(Fig. 2 A). At 1 h post LPS challenge, the TNFa levels were
identical in the ILIOT and wt mice. In the wt mice, serum
TNFa declined to almost undetectable levels 3-6 h after LPS.
However, TNFa continued to increase in the sera of ILIOT
mice and reached a peak concentration at 3 h that was 30-fold
higher than the amount detected in wt mice at 3 h. These high
levels of TNFa were maintained in the sera of ILlOT mice at
2340 Berg et al.
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6 h after LPS. Thus, both the kinetics and level ofTNFa produc-
tion were markedly altered in the absence of endogenous
IL-10.
Similar results were observed when the levels of IL-6 and
IL-12 were measured (Fig. 2 B and C). As expected, the appear-
ance of IL-6 and IL-12 in the sera of ILIOT and wt mice
occurred later than that of TNFa. While the levels of these two
cytokines declined in wt mice after 3 h, they continued to rise in
IL1OT mice. At 6 h post LPS, IL-6, and IL-12 were abnormally
increased in IL1OT mice by 70- and 6-fold, respectively. Addi-
tionally, p40 (the inducible subunit of IL-12), IL-lra (Fig. 2
D) and IFNy (Fig. 2 E) were much higher in the sera of IL1OT
mice.
Serum nitrate could not be detected in the sera of IL1OT or
wt mice before or within 6 h of LPS administration (data not
Figure 2. ILlOT mice have dysregulated cytokine
production after stimulation with endotoxin. LPS
(50 ,g/mouse) was administered i.v. and sera col-
lected at the indicated time points. Each data point
represents the mean±S.D. of 6-8 individual mice
per group. (A) TNFa, (B) IL-6, (C) IL-12 bioactiv-
ity and p40 protein concentration, (D) IL-la, and
(E) LFNy (left) and serum nitrate (right). Results
are representative of two independent experiments.
* Mann-Whitney U test, P < 0.05, demonstrating
statistical difference in serum levels between ILIOT
and wt mice groups. ND, not detected.
shown). However, very high levels were detected in the sera
of ILlOT mice at 12 h (data not shown) and 18 h post LPS
administration (Fig. 2 E). In contrast, nitrate remained unde-
tectable in the sera of wt mice at all time points tested (Fig.
2 E).
TNF and INFy are mediators of mortality in ILJOT mice
challenged with LPS. ILIOT mice were infused with neutraliz-
ing anti-cytokine Ab in order to determine which cytokine(s)
was contributing to their high mortality rate after challenge with
50 tig of LPS, a dose which was sublethal for wt mice. In these
experiments, 2 mg of anti-TNF Ab administered 4 h before LPS
challenge resulted in 70% survival whereas administration of 2
mg of the isotype control Ab provided no protection (Fig. 3).
Under the same experimental conditions, partial protection
of ILIOT mice (36% survival) was observed by administering
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Figure 3. Anti-TNF and anti-IFN-y Ab protects ILIOT mice from lethal
endotoxic shock. ILIOT mice received i.p. injections of anti-cytokine
antibody (anti-TNF, 2 mg; anti-IFN-y, 10 mg; anti-IL-6, 10 mg) or
isotype control antibody (GL-l 17, 2 or 10 mg) 4 h before challenge
with a lethal dose of LPS (50 pg/mouse, i.v.). Each treatment group
consisted of 8-10 mice. Surviving animals were monitored for 7 d.
Results are expressed as percentage of survival.
at least 10 mg of anti-IFNy Ab. Lower amounts of anti-INFy
(i.e., 2 mg) extended the survival of these mice but did not
ultimately prevent their death. The diminished mortality ob-
served in LPS-challenged ILIOT mice treated with the high dose
of anti-IFNy Ab demonstrates that this cytokine contributes to
their mortality. In contrast, the administration of anti-IL-6 Ab
(2-10 mg) failed to protect IL lOT mice from the lethal effects
of LPS (Fig. 3). Similar results were observed in wt mice
challenged with LPS (data not shown).
Endogenously produced IL-JO regulates early events in en-
dotoxic shock. Kinetic studies of IL-10 production were per-
formed in order to further analyze the role of this cytokine in
the regulation of the host's response to endotoxin. After chal-
lenge of wt mice with LPS (200 pg), it was found that serum
IL-10 levels peaked within 2 h of challenge (Fig. 4 A) and
remained detectable at 6 h. ILlOT mice challenged with LPS
did not produce detectable amounts of IL-10 in agreement with
previous studies (20). The ability of endogenous IL-10 to pro-
tect the host against the development of lethal endotoxic shock
was evaluated by administering anti-IL-10 Ab to wt mice at
different time points with respect to a sublethal LPS challenge
(50 jug/mouse). Neutralizing Ab to IL-10 administered 4 h
before LPS injection reduced the survival of the wt mice to
10% as compared with 100% survival in the isotype control-
treated group (Fig. 4 B). If the administration of the anti-IL-
10 Ab were delayed until 3 or 6 h after LPS, 90 and 100%
survival, respectively, were observed. These results indicate that
the events regulated by endogenous IL-10 occur early in endo-
toxic shock.
As IL1OT mice are deficient in the production of IL-10,
they were infused with exogenous IL-10 (10 4g) at various
times relative to a lethal dose of LPS in order to further define
IL-lO's regulatory effects. If IL-10 infusion were given at the
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None of the saline-treated control ILIOT mice survived (data not
shown). Each treatment group consisted of 6 to 8 ILIOT mice. Results
are representative of two independent experiments and expressed as
percentage of survival.
same time as LPS (50 /sg), 100% of the ILlOT mice survived.
However, if IL-10 infusion were delayed even 2 h after LPS
challenge, no survival was observed. Identical results were ob-
tained when a fivefold lower, but still lethal, LPS dose ( 10 4g)
was used (data not shown). These results confirmed that IL-10
must act early in order to block the pathogenic effects of LPS.
Our results also show that 90% of the ILIOT mice survived
when IL-1O was administered 4 h prior to LPS challenge. This
outcome suggested that IL-10 persisted in vivo long enough to
directly antagonize the actions of LPS or that IL-10 invoked
a state of unresponsiveness in LPS-sensitive cells. This latter
possibility was addressed in the studies described below.
The regulatory effects of IL-1O in the generalized Shwartz-
man reaction. The development of the generalized Shwartzman
reaction was compared in wt and ILIOT mice in order to evalu-
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Figure 5. ILIOT mice can be sensitized to LPS in the generalized
Shwartzman reaction. The Shwartzman reaction was elicited in ILIOT
mice by two consecutive injections of LPS. The preparatory injection
(0.005-0.1 pg LPS, f.p.) was followed 24 h later by a standard 2.5 yg
iv. provoking dose. Each group consisted of 6-8 ILIOT mice. Data are
representative of 3 independent experiments and results are expressed
as percentage of survival.
ate the role of endogenously produced IL-10 in controlling this
type of LPS-induced response. Extremely small amounts of
LPS (0.01-0.005 Mig LPS) injected into the f.p. of ILIOT mice
primed them for a lethal reaction to a sublethal dose of LPS
given i.v. 24 h later (Fig. 5). In contrast, a minimum dose of
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1 ,ug LPS was required to sensitize a wt mice for a lethal
reaction to a sublethal dose of LPS (data not shown). To further
evaluate this phenomenon, serum cytokines were measured at
various intervals after administration of the LPS elicitation dose.
Prior LPS sensitization of ILlOT mice lead to a transient but
significant increase in TNFa production (Fig. 6 A). In fact, the
highest amount of TNFa induced after two consecutive non-
lethal doses of LPS was similar to that induced by a single
lethal dose (see Fig. 2). In contrast, IL-6 and IFN-y serum levels
were not significantly altered by priming ILIOT mice with LPS
(Figs. 6, B and C). In both cases, the levels observed were low
as compared to those elicited by a single lethal dose of LPS
(see Fig. 2).
In another set of studies, we tested the ability of exogenous
IL-10 to regulate the priming phase of the generalized Shwartz-
man reaction. IL1OT and wt mice were given either IL-10 or
saline simultaneously with the priming dose of LPS (Table I).
As expected, we found that ILIOT and wt mice primed with
LPS had high mortality rates when challenged with sublethal
doses of LPS. In contrast, the mortality rates of both ILIOT and
wt mice were dramatically reduced if they were primed with
LPS in the presence of IL-10. These results clearly demonstrate
that the priming step in the Shwartzman reaction is inhibitable
by IL-1O.
ILIOT mice develop endotoxin tolerance. Numerous studies
have shown that prior exposure to low doses of LPS can result
in the development of tolerance to subsequent LPS challenge.
The possibility that the induction of tolerance might depend on
the actions of IL-10 prompted us to test whether ILIOT mice
could be rendered tolerant to LPS. When ILIOT mice were
primed with 1 pg of LPS in the f.p. and subsequently challenged
with a lethal i.v. dose of LPS (5 ig), all of the mice survived
(Fig. 7). ILlOT mice primed with 1 Mg of LPS survived subse-
quent challenges of 5-10 qg of LPS; however no survival was
seen when the mice were challenged with 25 Mug of LPS (data
not shown). Serum cytokines were measured at various inter-
6
Hours after LPS
elictation
0 Saline
0.005 Ig LPS,
prining dose
Figure 6. ILlOT mice sensitized to LPS in the Shwartzman reaction have exaggerated production of TNFa. ILIOT mice received either saline or
0.005 /ug LPS as a preparatory dose in the f.p. followed 24 h later by an eliciting dose of 2.5 4g LPS i.v. Sera for cytokine measurement by ELISA
were obtained at the indicated time points. Data represented are the mean±S.D. of 6-8 individual mice per group. (A) TNFa, (B) IL-6, and (C)
IFNy. * Mann-Whitney U test, P < 0.05, demonstrating statistical difference in the levels between LPS-primed and saline-treated ILIOT mice
groups.
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Table L IL-1O Inhibits the Priming Step in the Generalized
Shwartzman Reaction
IL-10 LPS LPS No. of
treatment priming elicitation mice deadl
Genotype i.p., 0 h f.p., 0 h i.v., 24 h tested Mortality
Agg Ag llg %
WT - 100 2/15 13
WT 10 100 0/13 0
WT 1 100 11/15 73
WT 10 1 100 1/15 6
ILlOT 2.5 0/10 0
ILlOT 10 2.5 0/10 0
ILIOT 0.005 2.5 8/15 53
ILIOT 10 0.005 2.5 2/10 20
The generalized Shwartzman reaction was elicited by two consecutive
injections of E. coli LPS. The preparatory injection f.p. (wt, 1 'qg LPS;
ILlOT, 0.005 pg LPS) followed after 24 h by an i.v. eliciting dose (wt,
100 Mg LPS; ILIOT, 2.5 Mg LPS). Saline or IL-0 (10 Ag) was adminis-
tered i.p. to the indicated groups. (-) indicates the administration of
saline. Data are pooled from two independent experiments.
vats after the LPS elicitation dose (5 Mg) and tolerance to a
lethal dose of LPS was correlated with decreased TNFa levels
(Fig. 8 A). No differences in IL-6 or IFNy levels were detected
(Fig. 8, B and C).
Next we evaluated the effect of exogenous IL-10 in the
development of endotoxin tolerance in wt and ILIOT mice (Ta-
ble II). It was found that IL-1O could not substitute for the LPS
priming dose, as no tolerance to the elicitating LPS dose could
be demonstrated. When IL-10 and the priming LPS dose were
administered simultaneously, the induction of tolerance was not
antagonized by IL-10. In fact, IL-0 administration appeared to
enhance the tolerizing effects of LPS in both wt and IL1OT
mice.
Discussion
We have used ILlOT and wt mice to further define the regula-
tory role of endogenous IL-10 in the immune/inflammatory
CUO
Figure 7. Endotoxin tol-
erance can be induced in
ILlOT mice. Tolerance
to LPS was elicited in
ILIOT mice by two con-
secutive LPS injections,
the preparatory injection
(0.1-1.0 gg, f.p.) was
followed 24 h later by a
5 Mtg i.v. eliciting dose.
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responses elicited in vivo by LPS. In a model of acute endotoxe-
mia, our comparative studies showed that the amount of LPS
which induced lethal endotoxic shock in ILlOT mice was at
least 20-fold lower than that required by wt mice. These results
suggest that the host's endogenous IL-10 level determines the
amount of endotoxin which constititutes a lethal threshold dose.
In support of this conclusion, it was found that infusing ILIOT
mice with 10 Mg of IL-I0 enabled them to survive a 10-fold
higher dose of LPS (50 Mg) than their untreated littermates.
Presumably, the administration of small doses of recombinant
IL-10 (0.5-1.0 Mig) used to protect normal mice from lethal
doses of LPS (16, 17) reflects the added protection gained by
boosting their endogenous IL-10 levels.
The high mortality rate observed in ILIOT mice challenged
with LPS was correlated with greatly elevated levels of serum
TNFa and INF-y. The heightened production of these two cyto-
kines in response to LPS had been observed in mice rendered
IL-10-deficient by anti-IL-10 Ab (19). Herein, high levels of
serum IL-la, IL-6, IL-12, and nitrate were also detected in the
sera of LPS-challenged ILIOT mice. Wt mice which survived
the same dose of LPS produced low, transient levels of serum
cytokines and no detectable nitrate. Although it was shown
previously that IL-10 was capable of suppressing the in vitro
production of these various pro-inflammatory mediators (12,
13), our studies with IL1OT mice and those using neutralizing
Ab (19) have demonstrated that endogenous IL-10 is essential
for controlling their in vivo production.
Even though a bolus i.v. injection of LPS induced the exag-
gerated production of multiple pro-inflammatory mediators in
IL-10-deficient mice, significant protection was provided by
prior treatment with anti-TNF Ab. These preliminary results
suggested that the uncontrolled production of TNF plays an
important role in the increased susceptibility of ILIOT mice to
endotoxic shock. It is well known that TNFa not only causes
tissue necrosis and organ failure, but is also a potent inducer
of the enzyme nitric oxide synthase which is required for the
production of nitric oxide (33). Nitric oxide has been implicated
in the induction of hypotension and vascular unresponsiveness
(34-36) associated with endotoxic shock. Because elevated
serum nitrate levels were observed in IL1OT mice but were
absent in normal mice stimulated with the same dose of LPS,
it seems likely that the unregulated production of nitric oxide
contributes to the high mortality rates observed in the IL1OT
mice. The exaggerated production of nitric oxide in response
to such low levels of LPS may reflect the absence of IL-1O's
regulatory effects on TNFa production.
Others have used a similar model of endotoxic shock to
show that the survival rates of normal mice challenged with
lethal doses of LPS were improved substantially by the adminis-
tration of anti-IFNy Ab (6, 10). Conversely, survival rates of
normal mice challenged with a LD50 of E. coli were greatly
diminished if the mice were pretreated with IFN-y (6). Further-
more, high mortality rates were observed in normal mice treated
with a combination of IFNy and TNFa at doses that were
nonlethal when administered alone (6). These latter studies
were intriguing since they suggested that IFN'y may play a
detrimental role by augmenting the pathogenic effects of TNFa.
The improved survival observed in LPS-challenged ILlOT mice
treated with anti-IFNy Ab supports the premise that IFNy con-
tributes to endotoxic shock. Although we did not use anti-IL-
1 Ab or IL1 receptor antagonist (IL-1RA) in this study, it has
been shown that these agents can prevent lethality in animal
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100 1
75 -
S
50'I
25 -
0
Downloaded on May 26, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/118290
E 40
a
4 30
-J
E 20
0
M I
301c
E
& 20
c
U-
10-
o
Hours after LPS Hours after LPS
elicitation elicitation
I1
Hours after LPS
elicitation
0 Saline
* 1.0 g LPS,
priming dose
Figure 8. IL1OT mice tolerized to LPS have decreased production of TNFa. IL1OT mice received either saline or 1.0 Ag LPS as a preparatory dose
in the f.p. followed after 24 h by an eliciting dose of 5 Mg LPS, i.v. Sera for cytokine measurement by ELISA were obtained at the indicated time
points. Data represented are the mean±S.D. of 6-8 individual mice per group. (A) TNFa, (B) IL-6, and (C) IFNy. *Mann-Whitney U test, P
< 0.05, demonstrating statistical difference in the levels between LPS-tolerized and saline-treated IL1OT mice groups.
models of sepsis (8, 9, 37). Clearly toxic shock is mediated by
a complex set of cytokine interactions (2-10). Thus, the lethal
threshold dose of LPS for ILlOT mice may be extremely low
as compared to that for wt mice because ILIOT mice are incapa-
ble of regulating not only TNFa production but also the produc-
tion of other mediators which may function as amplifiers (i.e.,
IFN-y and IL-1) or as effectors of endotoxic shock.
As we and others (18, 19) have found that IL-10 appears
in the sera of normal mice within 1 h after LPS challenge and
persists in their blood for at least 6 h, we investigated the
possibility that IL-1O may be important for directly suppressing
late as well as early events leading to endotoxic shock. Our
prelimary experiments confirmed that treatment of wt mice with
Table IL IL-IO Cannot Substitute for the LPS Priming Step in
Tolerance
IL-10 LPS LPS No. of
treatment priming elicitation mice alive/
Genotype i.p., 0 h f.p., 0 h i.v., 24 h tested Survival
lug jg jg S
WT 200 0/18 0
WT 10 - 200 0/15 0
WT 25 200 13/18 72
WT 10 25 200 18/18 100
ILIOT 10 0/15 0
ILlOT 10 10 0/15 0
ILIOT 1 10 13/15 87
ILIOT 10 1 10 15/15 100
Tolerance to LPS was elicited by two consecutive injections of E. coli
LPS. The preparatory f.p. injection (wt, 25 ttg LPS; ILIOT, 1 jsg LPS)
was followed 24 h later by an i.v. eliciting dose of LPS (wt, 200 ug
LPS; ILlOT, 10 Asg LPS). Saline or IL-10 (10 ,g) was administered i.p.
to the indicated groups. (-) indicates the administration of saline. Data
are pooled from two independent experiments.
anti-IL-lO Ab prior to challenge with a sublethal dose of LPS
resulted in high mortality rates (19). We also observed de-
creased survival in wt mice given anti-IL-10 Ab at the same
time as LPS but not when the Ab-treatment was delayed until
3 h after challenge. Based on the results of these in vivo kinetic
studies, it appeared that IL-1O mediates protection in the earliest
phase of the LPS response. In our studies with IL1OT mice, the
importance of IL-10 in controlling early and late events was
investigated by administering IL-10 at different times relative
to a low LD 10 (10 4g) and a high LD10 (50 1Lg) of LPS. We
found that IL1OT mice were completely protected if IL-10 were
administered just prior to or at the same time as LPS. The
failure of IL-10 to protect mice when administered even two
hours after challenge with either a low or high LD100 further
demonstrates that IL-10 plays a critical role in regulating early
events such as TNFa production. The pathological effects of
late appearing mediators, such as IENy and nitric oxide, are
most likely diminished as a consequence of IL-lO's suppressive
actions on TNFa production.
We have also investigated whether IL-1O plays a regulatory
role in the generalized Shwartzman reaction (21, 22). This
reaction requires two consecutive, relatively low doses of LPS
and is clinically manifested as a shock syndrome. Because the
amount, route and timing of the LPS injections are critical for
the phenomenon to occur, it was proposed that the Shwartzman
reaction is dependent on a cascade of inflammatory mediators
(38-40). Recently, it has been shown that the first dose of
LPS induces the production of IL-12 (41). IL-12 subsequently
stimulates the production of IFN-y which then prepares macro-
phages and other cell types to release large amounts of inflam-
matory cytokines in response to the second, provoking dose of
LPS (41). It appears that TNFa is the critical effector of lethal-
ity in primed mice but its actions require the presence of either
IL-la or INF-y (39, 41). After recognizing that the sequential
actions of very specific cytokines are involved in generating
the Shwartzman reaction (41) and based on what was known
about the in vitro kinetics of IL-10 production (12), it was
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predicted (41 ) that any putative inhibitory effects of endoge-
nous IL-1O would occur only during the second LPS challenge.
However, our comparative studies have shown that only minis-
cule amounts of LPS were required to prime ILIOT mice for
the enhanced release of TNFa. The finding that 200-fold more
LPS was needed to prime wt mice suggests that endogenous
IL-10 normally inhibits IL-12 and IFN-y production in response
to small amounts of LPS during the prepatory phase.
In support of this conclusion, we formally demonstrated that
IL-10 is capable of blocking LPS priming in the Shwartzman
reaction. Hence, IL-lOT and wt mice primed with LPS together
with IL-10 were protected from a lethal provoking LPS dose.
When cytokine levels in the serum of primed and unprimed
IL1OT mice were compared, no differences were observed in
their IL-6 or IFNy production after LPS challenge. However,
elevated TNFa levels were found in the primed mice further
indicating that alterations in TNFa production are a necessary
prerequisite for a lethal Shwartzman reaction (39, 41). These
results also support the conclusion that IL-10 normally sup-
presses the host's reactions to minimal amounts of LPS thus
preventing increased susceptibility to systemic shock.
Tolerance to endotoxin can develop in animals exposed re-
peatedly to sublethal doses of LPS or exposed to a single low
dose of LPS albeit higher than that used to prime for the
Shwartzman reaction (23). Tolerance occurs rapidly (24-96
h) and has been correlated with the suppressed production of
inflammatory mediators (23, 39, 42). It has been proposed
that hyporesponsiveness may result from the induction of both
inflammatory and anti-inflammatory factors following exposure
to LPS. The supernatants of macrophages tolerized in vitro to
LPS have been shown to contain a factor capable of rendering
naive macrophages refractory to LPS stimulation (43). We have
tested the possibility that IL- IO is the factor responsible for LPS-
induced tolerance. The results of our studies clearly suggest
otherwise since certain doses of LPS could establish a state of
hyporesponsiveness in ILlOT mice. As a result, the survival
rate upon lethal LPS challenge was 87% as compared with 0%
in the untolerized group. Evaluation of cytokines in the sera of
tolerized ILlOT mice showed that protection correlated with
suppressed TNFa production; no alterations were seen in either
IL-6 or IFNy production.
A potential role for IL-10 in establishing LPS-induced toler-
ance was further evaluated by administering exogenous IL-10
to IL-lOT and wt mice. Herein, it was shown that IL-10 infusion
could not substitute for LPS in eliciting tolerance since none
of the IL-10-treated animals survived a subsequent lethal LPS
challenge. Nevertheless, the injection of IL-10 together with
LPS during the desensitization step resulted in a slight enhance-
ment of the survival rate (100%) over that obtained with just
LPS (72 and 87%). Collectively, our results show that the
mechanism of LPS-induced tolerance is not dependent on IL-
10, although IL-10 may serve to potentiate the process. Several
anti-inflammatory factors are produced in response to LPS and
may mediate acquired tolerance to endotoxin. Examples include
the IL-IRA (44) and IL-6 (45). Other possibilities include
modulation of the LPS receptor or post-receptor events after
LPS stimulation (46,47) as well as the production of the protein
BPI (bactericidal/permeability-increasing protein) from LPS-
activated PMNs (48). It is interesting to note that the production
of one of these anti-inflammatory agents, the IL-IRA, has al-
ready been shown to be enhanced by IL-10 (49-51).
The host's reactivity to LPS is a key part of a defensive
immune/inflammatory response to gram-negative bacteria.
Containment and elimination of infectious organisms are ac-
complished in part through the production of inflammatory me-
diators, however, excessive production of these same mediators
can result in pathology ranging from tissue damage to lethal
endotoxic shock. Regulatory mechanisms have evolved to limit
immune/inflammatory responses in order to avoid immunopath-
ologic damage. Our studies demonstrate that IL-10 has a central
role in regulating the host's response to endotoxin. The ability
of IL- 10 to suppress directly or indirectly the LPS-induced pro-
duction of pro-inflammatory mediators appears critical in de-
termining the host's susceptibility to pathogenic reactions as no
compensatory mechanisms existed in the ILIOT mice which
substituted for the IL-10 deficiency. Our studies also suggest
that IL-10 may have a therapeutic role in the modification of
responses to LPS.
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